Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark C Smith

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Immunology and Cell Biology|May 27, 2009
Optimization of LMP-specific CTL expansion for potential adoptive immunotherapy in NPC patientsViviana P Lutzky, Joanne E Davis, Pauline Crooks, et al.
Pathology Oncology Research : POR|October 29, 2017
Is More Always Better? An Assessment of the Impact of Lymph Node Yield on Outcome for Clinically Localized Prostate Cancer with Low/Intermediate Risk Pathology (pT2-3a/pN0) Managed with Prostatectomy AloneSteven N Seyedin, Darrion L Mitchell, Sarah L Mott, et al.
International Journal of Radiation Oncology, Biology, Physics|July 3, 2014
3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapyManickam Muruganandham, Patrick P Clerkin, Brian J Smith, et al.
Advances in Radiation Oncology|December 22, 2021
A Recursive Partitioning Analysis Demonstrating Risk Subsets for 8-Year Biochemical Relapse After Margin-Positive Radical Prostatectomy Without Adjuvant Hormone or Radiation TherapySteven N Seyedin, John M Watkins, Zachary Mayo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2019
First-in-Human Phase I Clinical Trial of Pharmacologic Ascorbate Combined with Radiation and Temozolomide for Newly Diagnosed GlioblastomaBryan G Allen, Kellie L Bodeker, Mark C Smith, et al.
Redox Biology|December 1, 2020
Magnetic resonance imaging (MRI) of pharmacological ascorbate-induced iron redox state as a biomarker in subjects undergoing radio-chemotherapyCameron M Cushing, Michael S Petronek, Kellie L Bodeker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2023
Magnetic Resonance Imaging of Iron Metabolism with T2* Mapping Predicts an Enhanced Clinical Response to Pharmacologic Ascorbate in Patients with GBMMichael S Petronek, Varun Monga, Kellie L Bodeker, et al.
Cancer Cell|August 16, 2017
O<sub>2</sub><sup>⋅-</sup> and H<sub>2</sub>O<sub>2</sub>-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological AscorbateJoshua D Schoenfeld, Zita A Sibenaller, Kranti A Mapuskar, et al.
Cancer Cell|April 4, 2017
O<sub>2</sub><sup>⋅-</sup> and H<sub>2</sub>O<sub>2</sub>-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological AscorbateJoshua D Schoenfeld, Zita A Sibenaller, Kranti A Mapuskar, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Immunology and Cell Biology|May 27, 2009
Optimization of LMP-specific CTL expansion for potential adoptive immunotherapy in NPC patientsViviana P Lutzky, Joanne E Davis, Pauline Crooks, et al.
Pathology Oncology Research : POR|October 29, 2017
Is More Always Better? An Assessment of the Impact of Lymph Node Yield on Outcome for Clinically Localized Prostate Cancer with Low/Intermediate Risk Pathology (pT2-3a/pN0) Managed with Prostatectomy AloneSteven N Seyedin, Darrion L Mitchell, Sarah L Mott, et al.
International Journal of Radiation Oncology, Biology, Physics|July 3, 2014
3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapyManickam Muruganandham, Patrick P Clerkin, Brian J Smith, et al.
Advances in Radiation Oncology|December 22, 2021
A Recursive Partitioning Analysis Demonstrating Risk Subsets for 8-Year Biochemical Relapse After Margin-Positive Radical Prostatectomy Without Adjuvant Hormone or Radiation TherapySteven N Seyedin, John M Watkins, Zachary Mayo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2019
First-in-Human Phase I Clinical Trial of Pharmacologic Ascorbate Combined with Radiation and Temozolomide for Newly Diagnosed GlioblastomaBryan G Allen, Kellie L Bodeker, Mark C Smith, et al.
Redox Biology|December 1, 2020
Magnetic resonance imaging (MRI) of pharmacological ascorbate-induced iron redox state as a biomarker in subjects undergoing radio-chemotherapyCameron M Cushing, Michael S Petronek, Kellie L Bodeker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2023
Magnetic Resonance Imaging of Iron Metabolism with T2* Mapping Predicts an Enhanced Clinical Response to Pharmacologic Ascorbate in Patients with GBMMichael S Petronek, Varun Monga, Kellie L Bodeker, et al.
Cancer Cell|August 16, 2017
O<sub>2</sub><sup>⋅-</sup> and H<sub>2</sub>O<sub>2</sub>-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological AscorbateJoshua D Schoenfeld, Zita A Sibenaller, Kranti A Mapuskar, et al.
Cancer Cell|April 4, 2017
O<sub>2</sub><sup>⋅-</sup> and H<sub>2</sub>O<sub>2</sub>-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological AscorbateJoshua D Schoenfeld, Zita A Sibenaller, Kranti A Mapuskar, et al.
Pageof 5